Alto Neuroscience, Inc. (ANRO) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Alto Neuroscience, Inc. on July 13, 2026. The Company, an emerging growth company incorporated in Delaware, is reporting the entry into a material definitive agreement regarding a registered direct offering of its common stock.
Key Financial Metrics and Transaction Details
- Transaction Type: Underwritten registered direct offering.
- Shares Issued: 3,776,436 shares of Common Stock.
- Offering Price: $26.48 per share.
- Estimated Net Proceeds: Approximately $93.9 million (after underwriting discounts, commissions, and estimated offering expenses).
- Underwriters: BofA Securities, Inc. (representative), Stifel, Nicolaus & Company, Incorporated, William Blair & Company, L.L.C., and Robert W. Baird & Co. Incorporated (joint book-running managers); JonesTrading Institutional Services LLC and H.C. Wainwright & CO., LLC (co-managers).
- Expected Closing Date: July 14, 2026.
Note: This filing does not provide specific revenue, profit, cash flow, margin, or debt figures for the Company. It focuses solely on the capital raise transaction.
Material Changes and Use of Proceeds
The primary material change is the increase in equity capital through the sale of new shares. The Company intends to use the net proceeds, combined with existing cash and cash equivalents, for the following purposes:
- Accelerate and expand the clinical development of its lead asset, ALTO-207.
- Conduct an additional planned Phase 3 trial of ALTO-207 as a monotherapy for the treatment of treatment-resistant depression.
- General working capital purposes.
Guidance, Risks, and Forward-Looking Statements
The filing contains forward-looking statements regarding the completion of the Offering, the net proceeds, and the anticipated use of funds. Management cautions that actual results may differ materially due to risks and uncertainties, including market conditions and the ability to complete the Offering on anticipated terms. The Company disclaims any obligation to update these statements except as required by law. Detailed risk factors are referenced in the Company's Annual Report on Form 10-K for the year ended December 31, 2025.
Key Facts for Investor Verification
- Verify the final closing of the Offering on or around July 14, 2026, and the actual net proceeds received.
- Monitor the dilution impact of the issuance of 3,776,436 new shares on existing shareholders.
- Track the specific allocation of funds toward the Phase 3 trial of ALTO-207 for treatment-resistant depression.
- Review the full Underwriting Agreement (Exhibit 1.1) for specific covenants, indemnification obligations, and termination provisions.